Omeros Corp. (0KBU)
LSE
Delayed Data
Oct 20, 2026, 07:00 AM
Day's Range
16.2752 wk Range
6.28Overview - 0KBU - Omeros Corp.
Key Statistics
Valuation
Enterprise Value
1.59B
P/E (Trailing)
‪0.06‬
EV / EBITDA
‪-22.24‬
Profitability
Profit Margin
‪324.88%‬
Operating Margin
‪0.25%‬
Return on Assets
‪-18.67%‬
Ownership
Shares Outstanding
49.00M
Float
69.28M
Held by Insiders
‪4.08%‬
Held by Institutions
‪51.42%‬
Price stats
Beta
‪2.57‬
50-Day Avg
‪3.74‬
200-Day Avg
‪4.07‬
Market Cap - 0KBU - Omeros Corp.
Peers - 0KBU - Omeros Corp.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0KBULSEOmeros Corp.971.36MMarket Cap+79.26%52-week change0.06P/E (Trailing)‪324.88%‬Profit Margin
- 0MGBLSEGenmab A/S207.40BMarket Cap+25.18%52-week change36.60P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated Common Stock129.06BMarket Cap+14.69%52-week change52.74P/E (Trailing)‪34.99%‬Profit Margin
- 0A45LSEModerna Inc.107.69BMarket Cap+88.04%52-week change84.05P/E (Trailing)‪11.32%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.81.30BMarket Cap+23.54%52-week change10.70P/E (Trailing)‪27.86%‬Profit Margin
- 0QW0LSEargenx SE43.34BMarket Cap+6.62%52-week change34.95P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA41.70BMarket Cap-23.62%52-week change120.56P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0KBU - Omeros Corp.
About
Omeros Corp. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. The company concentrates on immunologic and complement-mediated diseases, along with selected orphan and rare indications affecting inflammation, coagulopathies,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
